comparemela.com

Latest Breaking News On - Flow cell - Page 1 : comparemela.com

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

South-korea
Busan
Pusan-gwangyoksi
Subra-sankar
Carrie-mendivil
Bernd-wollscheid
Daniel-brennan
Sujal-patel
Yuko-oku
Martin-huber
Parag-mallick
Anna-mowry

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteomeSEATTLE, Nov. 01, 2023 .

Vienna
Wien
Austria
Martin-huber
Subra-sankar
Nasdaq
Nautilus-biotechnology-inc
Product-development-at-nautilus
University-of-vienna
Flow-cell-development
Former-quantapore
Vice-president

Nautilus Biotechnology Inc.: Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Nautilus Biotechnology Inc.: Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Austria
Vienna
Wien
Martin-huber
Subra-sankar
Flow-cell-development
University-of-vienna
Product-development-at-nautilus
Nasdaq
Nautilus-biotechnology-inc
Vice-president
Flow-cell

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively.

Vienna
Wien
Austria
Martin-huber
Subra-sankar
Product-development-at-nautilus
Nautilus-biotechnology-inc
Flow-cell-development
University-of-vienna
Nasdaq
Vice-president
Flow-cell

MGI Partners with National Cancer Centre Singapore

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

Singapore
United-states
Asia-pacific
Jason-chan
Tech-singapore-pte-ltd
National-cancer-centre-singapore
Tech-co-ltd
Lab-initiative
Research-use
Singapore-pte
Roy-tan
General-manager

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.